Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroDex

Full company profile

uuid0008o4d

Namestring
NeuroDex
Legal namestring
NeuroDex Inc.
Websiteurl
neurodex.co
Company typeenum
Private
Founded yearint
2018
Descriptiontext

NeuroDex is a private biotechnology company headquartered at 22 Strathmore Road, Natick, Massachusetts (founded circa 2019), that develops blood-based biomarker diagnostics and bioanalytical services for neurological disorders. The company operates Neurodex Laboratories, a GLP-compliant and CLIA-certified facility, and serves pharmaceutical and biotechnology sponsors developing therapeutics for Alzheimer's, Parkinson's, ALS, FTD, and other neurodegenerative conditions, as well as academic medical centers and disease foundations funding translational neuroscience research.

The company's core technology is the ExoSort Platform, a proprietary immunoaffinity isolation system that selectively isolates neuron-derived extracellular vesicles (NDEs) from plasma. This enables brain-specific biomarker analysis from a simple blood draw rather than lumbar puncture, and runs in an automated 96-well plate format with low within- and between-batch variability. Building on ExoSort, the Neurodiagnostic Platform offers validated biomarker panels — α-Syn (Parkinson's, MSA, Alzheimer's), TDP43 (ALS, FTD, Alzheimer's), Tau/pTau (Alzheimer's), NF-L (brain injury, neuroinflammation), LC3 (autophagy), NF-kB (neuroinflammation), AKT (metabolic), and synaptic proteins — used for pharmacodynamic monitoring, patient stratification, and endpoint analysis. The company has also developed an Alpha-Synuclein Seed Amplification Assay (αSyn-SAA) using RT-QuIC technology for early Parkinson's detection.

NeuroDex operates a project-based, sales-led B2B business model with quote-based, non-public pricing. Revenue is generated through four streams: biomarker discovery services (immunoassay- and RNA-seq-based), translational research collaborations with pharma and biotech, clinical trial biomarker support for Phase I–III studies, and Research Use Only consumables (plates, assays, reagents). Customer and partner logos include Alkermes, QurAlis, NeuroSense, SBH Science, Yale University, Stanford University, Johns Hopkins University, Massachusetts General Hospital, Trieste University, the Michael J. Fox Foundation, the Alzheimer's Drug Discovery Foundation, and the NIH. Scientific credibility is reinforced through peer-reviewed publications (notably in the Journal of Extracellular Biology) and participation in industry conferences including AAIC 2024.

Short descriptiontext

NeuroDex is a Natick, Massachusetts-based biotechnology company developing blood-based neuron-derived extracellular vesicle (NDE) biomarker diagnostics and bioanalytical services for pharmaceutical, biotech, and academic clients working on Alzheimer's, Parkinson's, ALS, and other neurological disease therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNatick, United States
HQ citystring
Natick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurological biomarker discovery, extracellular vesicle isolation, neurodegenerative disease diagnostics, clinical trial biomarker services, precision neurology platforms
Industry3 codes
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Neurological Biomarker Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Biomarker Discovery Services
TypeProfessional Services
Description

Leverage brain-enriched exosomes to discover novel biomarkers for neurological diseases using immunoassays and RNA sequencing. Project-based research collaborations with pharmaceutical and biotech companies.

neurodex.co
2Translational Research Biomarkers
TypeProfessional Services
Description

Partnering with pharmaceutical and biotechnology companies to translate NDE biomarkers into clinically relevant endpoints for drug development. Collaborative development arrangements.

neurodex.co
3Clinical Trial Biomarker Support
TypeProfessional Services
Description

Biomarker services tailored for integration into Phase I–III clinical trials including stratification, pharmacodynamic monitoring, and endpoint analysis. Contract-based service revenue.

neurodex.co
4Neurodiagnostic Platform Products
TypeOne Time License
Description

Sale of biomarker assay plates, assays, and reagents (consumables) for neurological disease detection and monitoring. Products sold under research use only terms.

neurodex.co
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Research Use Only (RUO) Products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products include plates, assays, and reagents (consumables). Pricing published or quoted by representatives may be changed without notice. List prices may vary from website displayed prices. Warranty period of one year from acceptance for consumables.

neurodex.co
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NeuroDex develops and delivers biomarker discovery, translational research, and clinical trial support services built on its proprietary ExoSort Platform for isolating neuron-derived extracellular vesicles (NDEs) from blood samples. The company sells biomarker assay plates, assays, and reagents as research-use-only products and provides end-to-end biomarker solutions for pharmaceutical, biotechnology, and academic clients targeting Parkinson's, Alzheimer's, ALS, and neuroinflammatory diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 90% sensitivity and specificity for α-syn-SAA detection of Parkinson's pathology in prodromal stages
+2 more records
Product overview1 text field

NeuroDex is a biotechnology company offering a unified platform centered on the ExoSort Platform for isolating neuron-derived extracellular vesicles (NDEs) and the Neurodiagnostic Platform featuring multiple validated biomarker panels (α-Syn, TDP43, Tau/pTau, NF-L, LC3, NF-kB, AKT, Synaptic Protein). The portfolio includes complementary laboratory services provided through Neurodex Laboratories (GLP/CLIA compliant), Biomarker Discovery Services, Translational Research Biomarkers, Pre-Clinical Research Services, and Clinical Trial Services. These offerings work together to provide end-to-end biomarker solutions from discovery through clinical validation for neurological disorders including Parkinson's, ALS, Alzheimer's, and neuroinflammatory diseases.

Product and service7 records
1ExoSort Platform
CategoryBiomarker Platform Technology
Description

Proprietary immunoaffinity isolation platform for capturing neuron-derived extracellular vesicles (NDEs) from blood samples, enabling brain-specific biomarker analysis from plasma without invasive procedures. Offered to pharmaceutical, biotechnology, and academic customers for neurological disease research.

2Neurodiagnostic Platform
CategoryBiomarker Assay Platform
Description

A biomarker platform featuring validated panels including α-Syn (Parkinson's, MSA, Alzheimer's), TDP43 (ALS, FTD), Tau/pTau (Alzheimer's), NF-L (brain injury, neuroinflammation), LC3 (autophagy/lysosome), NF-kB (neuroinflammation), AKT panel (metabolic changes), and Synaptic Protein (synaptic plasticity) for monitoring disease progression and treatment response.

3Neurodex Laboratories
CategoryLaboratory Services
Description

GLP-compliant and CLIA-certified laboratory providing biomarker analysis services, with full assay validation expected Q2 2026. Services span biomarker discovery, translational research, and clinical trial support.

4Biomarker Discovery Services
CategoryResearch Services
Description

Leverages brain-enriched exosomes to discover novel biomarkers for neurological diseases using immunoassays and RNA sequencing. Project-based research collaborations with pharmaceutical and biotechnology companies.

5Clinical Trial Services
CategoryClinical Trial Services
Description

Biomarker services tailored for integration into Phase I–III clinical trials, including patient stratification, pharmacodynamic monitoring, and endpoint analysis. Offered to pharmaceutical and biotechnology sponsors.

6Pre-Clinical Research Services
CategoryPre-Clinical Research Services
Description

Pre-clinical biomarker services supporting drug development studies prior to human trials. Offered to pharmaceutical and biotechnology companies advancing neurological disease therapeutics.

7Alpha-Synuclein Seed Amplification Assay (αSyn-SAA)
CategoryDiagnostic Assay
Description

Diagnostic technology using RT-QuIC (Real-Time Quaking-Induced Conversion) to detect pathological, seeding-competent forms of alpha-synuclein for early Parkinson's disease detection and clinical trial stratification, achieving over 90% sensitivity and specificity for prodromal Parkinson's pathology.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration on CNS target engagement studies. Published first evidence of CNS target engagement for GLP-1 and PPARγ agonists using blood-based neuron-derived extracellular vesicles. Multi-institution research partnership advancing neurological biomarker science.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership in biomarker discovery and validation. Collaborates on neurological disease research leveraging NeuroDex's NDE isolation technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with MGH Biomarker Discovery Lab on tissue samples and biomarker validation for neurological disease research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership for biomarker discovery and validation in neurological disorders.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biotechnology company partnership for ALS and neurological disease biomarker research collaboration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biotechnology company partnership for neurological biomarker research and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical company partnership for translational research biomarkers and drug development endpoint validation.

8SBH Science
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scientific research collaboration in biomarker discovery services.

neurodex.co
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Awarded Target ALS Biomarker Consortia Grant in 2024 to develop ALS biomarker by analyzing neuron-derived extracellular vesicles. Goal is minimally invasive method to monitor ALS progression and treatment response.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-profit research foundation partnership for Parkinson's disease biomarker research and funding.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-profit foundation partnership for Alzheimer's disease biomarker research and drug discovery funding.

12NIH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Government research funding agency partnership for neurological disease research funding and collaboration.

neurodex.co
13Trieste University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

International academic partnership for neurological biomarker research collaboration.

neurodex.co
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Although primarily inflammation-focused, Evelo represents the broader class of emerging biomarker-driven biotechs that compete for the same pharma partnership and grant funding pool as NeuroDex.

2ADx NeuroSciences
TypeDirect peer
Description

Specialized biomarker assay developer focused on neurodegenerative disease diagnostics (Alzheimer's, Parkinson's). Provides complementary and competing immunoassays for CNS drug development.

3Simoa Neurology Biomarker Consortia (academic core labs e.g., Sahlgrenska, ADNI)
TypeOthers
Description

Academic biomarker core labs running in-house immunoassays for pharma-sponsored studies. They compete indirectly for translational research budgets and provide a benchmark for in-sourcing vs. outsourcing biomarker work.

TypeBroad incumbent
Description

Large life sciences tools company with extensive neuroscience biomarker reagents, ELISA kits, and proteomics platforms. Competes across NeuroDex's RUO consumables business and serves overlapping pharma/academic customers.

TypeBroad incumbent
Description

Major clinical diagnostics company with established neurology biomarker menu including CSF assays for AD. Represents a potential IVD partner or competitive incumbent in regulated CNS diagnostics.

TypeEmerging player
Description

Ultra-sensitive proteomics platform (NULISA) targeting neurology and inflammation biomarkers. Emerging alternative to NDE-based approaches for CNS biomarker measurement in clinical trials.

TypeDirect peer
Description

Simoa ultra-sensitive immunoassay platform widely used for neurology biomarker detection (NfL, p-Tau). Provides competing biomarker measurement technology serving overlapping pharma and academic customers.

TypeDirect peer
Description

Commercial-stage blood-based diagnostics for Alzheimer's disease (PrecivityAD) with CLIA-certified lab. Competes for pharma AD trial stratification contracts and shares NeuroDex's neurology biomarker services model.

TypeDirect peer
Description

Develops Seed Amplification Assays (SAA/RT-QuIC) for synucleinopathies including Parkinson's and MSA. Directly comparable to NeuroDex's αSyn-SAA diagnostic offering and competes for the same clinical trial biomarker opportunities.

TypeBroad incumbent
Description

Global diagnostics leader with Elecsys neurology biomarker assays (p-Tau181, NfL, GFAP) deployed on widespread clinical instrumentation. Sets pricing and standards in the CNS IVD market NeuroDex aspires to enter.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroDex

Neurological Biomarker Servicesneurodex.co

NeuroDex is a Natick, Massachusetts-based biotechnology company developing blood-based neuron-derived extracellular vesicle (NDE) biomarker diagnostics and bioanalytical services for pharmaceutical, biotech, and academic clients working on Alzheimer's, Parkinson's, ALS, and other neurological disease therapeutics.

What NeuroDex does

NeuroDex is a private biotechnology company headquartered at 22 Strathmore Road, Natick, Massachusetts (founded circa 2019), that develops blood-based biomarker diagnostics and bioanalytical services for neurological disorders. The company operates Neurodex Laboratories, a GLP-compliant and CLIA-certified facility, and serves pharmaceutical and biotechnology sponsors developing therapeutics for Alzheimer's, Parkinson's, ALS, FTD, and other neurodegenerative conditions, as well as academic medical centers and disease foundations funding translational neuroscience research.

The company's core technology is the ExoSort Platform, a proprietary immunoaffinity isolation system that selectively isolates neuron-derived extracellular vesicles (NDEs) from plasma. This enables brain-specific biomarker analysis from a simple blood draw rather than lumbar puncture, and runs in an automated 96-well plate format with low within- and between-batch variability. Building on ExoSort, the Neurodiagnostic Platform offers validated biomarker panels — α-Syn (Parkinson's, MSA, Alzheimer's), TDP43 (ALS, FTD, Alzheimer's), Tau/pTau (Alzheimer's), NF-L (brain injury, neuroinflammation), LC3 (autophagy), NF-kB (neuroinflammation), AKT (metabolic), and synaptic proteins — used for pharmacodynamic monitoring, patient stratification, and endpoint analysis. The company has also developed an Alpha-Synuclein Seed Amplification Assay (αSyn-SAA) using RT-QuIC technology for early Parkinson's detection.

NeuroDex operates a project-based, sales-led B2B business model with quote-based, non-public pricing. Revenue is generated through four streams: biomarker discovery services (immunoassay- and RNA-seq-based), translational research collaborations with pharma and biotech, clinical trial biomarker support for Phase I–III studies, and Research Use Only consumables (plates, assays, reagents). Customer and partner logos include Alkermes, QurAlis, NeuroSense, SBH Science, Yale University, Stanford University, Johns Hopkins University, Massachusetts General Hospital, Trieste University, the Michael J. Fox Foundation, the Alzheimer's Drug Discovery Foundation, and the NIH. Scientific credibility is reinforced through peer-reviewed publications (notably in the Journal of Extracellular Biology) and participation in industry conferences including AAIC 2024.

NeuroDex firmographics

Firmographics
Name
NeuroDex
Legal name
NeuroDex Inc.
Website
https://neurodex.co
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuroDex is a Natick, Massachusetts-based biotechnology company developing blood-based neuron-derived extracellular vesicle (NDE) biomarker diagnostics and bioanalytical services for pharmaceutical, biotech, and academic clients working on Alzheimer's, Parkinson's, ALS, and other neurological disease therapeutics.
Ownership category
akta.pro rank

NeuroDex industry classification

Industry
Product category
Neurological Biomarker Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Neurological biomarker discovery
  • Extracellular vesicle isolation
  • Neurodegenerative disease diagnostics
  • Clinical trial biomarker services
  • Precision neurology platforms

Where NeuroDex is headquartered

Location

Headquarters

HQ city
Natick
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuroDex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biomarker Discovery Services: Leverage brain-enriched exosomes to discover novel biomarkers for neurological diseases using immunoassays and RNA sequencing. Project-based research collaborations with pharmaceutical and biotech companies.
  2. Translational Research Biomarkers: Partnering with pharmaceutical and biotechnology companies to translate NDE biomarkers into clinically relevant endpoints for drug development. Collaborative development arrangements.
  3. Clinical Trial Biomarker Support: Biomarker services tailored for integration into Phase I–III clinical trials including stratification, pharmacodynamic monitoring, and endpoint analysis. Contract-based service revenue.
  4. Neurodiagnostic Platform Products: Sale of biomarker assay plates, assays, and reagents (consumables) for neurological disease detection and monitoring. Products sold under research use only terms.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goResearch Use Only (RUO) Products

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

NeuroDex product offering

Product offering

Core offering

NeuroDex develops and delivers biomarker discovery, translational research, and clinical trial support services built on its proprietary ExoSort Platform for isolating neuron-derived extracellular vesicles (NDEs) from blood samples. The company sells biomarker assay plates, assays, and reagents as research-use-only products and provides end-to-end biomarker solutions for pharmaceutical, biotechnology, and academic clients targeting Parkinson's, Alzheimer's, ALS, and neuroinflammatory diseases.

Product overview

NeuroDex is a biotechnology company offering a unified platform centered on the ExoSort Platform for isolating neuron-derived extracellular vesicles (NDEs) and the Neurodiagnostic Platform featuring multiple validated biomarker panels (α-Syn, TDP43, Tau/pTau, NF-L, LC3, NF-kB, AKT, Synaptic Protein). The portfolio includes complementary laboratory services provided through Neurodex Laboratories (GLP/CLIA compliant), Biomarker Discovery Services, Translational Research Biomarkers, Pre-Clinical Research Services, and Clinical Trial Services. These offerings work together to provide end-to-end biomarker solutions from discovery through clinical validation for neurological disorders including Parkinson's, ALS, Alzheimer's, and neuroinflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • ExoSort Platform Proprietary immunoaffinity isolation platform for capturing neuron-derived extracellular vesicles (NDEs) from blood samples, enabling brain-specific biomarker analysis from plasma without invasive procedures. Offered to pharmaceutical, biotechnology, and academic customers for neurological disease research.
  • Neurodiagnostic Platform A biomarker platform featuring validated panels including α-Syn (Parkinson's, MSA, Alzheimer's), TDP43 (ALS, FTD), Tau/pTau (Alzheimer's), NF-L (brain injury, neuroinflammation), LC3 (autophagy/lysosome), NF-kB (neuroinflammation), AKT panel (metabolic changes), and Synaptic Protein (synaptic plasticity) for monitoring disease progression and treatment response.
  • Neurodex Laboratories GLP-compliant and CLIA-certified laboratory providing biomarker analysis services, with full assay validation expected Q2 2026. Services span biomarker discovery, translational research, and clinical trial support.
  • Biomarker Discovery Services Leverages brain-enriched exosomes to discover novel biomarkers for neurological diseases using immunoassays and RNA sequencing. Project-based research collaborations with pharmaceutical and biotechnology companies.
  • Clinical Trial Services Biomarker services tailored for integration into Phase I–III clinical trials, including patient stratification, pharmacodynamic monitoring, and endpoint analysis. Offered to pharmaceutical and biotechnology sponsors.
  • Pre-Clinical Research Services Pre-clinical biomarker services supporting drug development studies prior to human trials. Offered to pharmaceutical and biotechnology companies advancing neurological disease therapeutics.
  • Alpha-Synuclein Seed Amplification Assay (αSyn-SAA) Diagnostic technology using RT-QuIC (Real-Time Quaking-Induced Conversion) to detect pathological, seeding-competent forms of alpha-synuclein for early Parkinson's disease detection and clinical trial stratification, achieving over 90% sensitivity and specificity for prodromal Parkinson's pathology.

Quantifiable outcome

  • Over 90% sensitivity and specificity for α-syn-SAA detection of Parkinson's pathology in prodromal stages
  • +2 more outcomes

Companies that use NeuroDex

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles3 records

NeuroDex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NeuroDex partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Stanford UniversitycoreStrategic or Co-development PartnerResearch collaboration on CNS target engagement studies. Published first evidence of CNS target engagement for GLP-1 and PPARγ agonists using blood-based neuron-derived extracellular vesicles. Multi-institution research partnership advancing neurological biomarker science.
  • Yale UniversitycoreStrategic or Co-development PartnerAcademic research partnership in biomarker discovery and validation. Collaborates on neurological disease research leveraging NeuroDex's NDE isolation technology.
  • Massachusetts General HospitalcoreStrategic or Co-development PartnerResearch collaboration with MGH Biomarker Discovery Lab on tissue samples and biomarker validation for neurological disease research.
  • Johns Hopkins UniversitycoreStrategic or Co-development PartnerAcademic research partnership for biomarker discovery and validation in neurological disorders.
  • QurAlisminorStrategic or Co-development PartnerBiotechnology company partnership for ALS and neurological disease biomarker research collaboration.
  • NeuroSenseminorStrategic or Co-development PartnerBiotechnology company partnership for neurological biomarker research and development.
  • AlkermescoreStrategic or Co-development PartnerPharmaceutical company partnership for translational research biomarkers and drug development endpoint validation.
  • SBH ScienceminorStrategic or Co-development PartnerScientific research collaboration in biomarker discovery services.
  • Target ALScoreStrategic or Co-development PartnerAwarded Target ALS Biomarker Consortia Grant in 2024 to develop ALS biomarker by analyzing neuron-derived extracellular vesicles. Goal is minimally invasive method to monitor ALS progression and treatment response.
  • Michael J. Fox FoundationcoreStrategic or Co-development PartnerNon-profit research foundation partnership for Parkinson's disease biomarker research and funding.
  • Alzheimer's Drug Discovery FoundationcoreStrategic or Co-development PartnerNon-profit foundation partnership for Alzheimer's disease biomarker research and drug discovery funding.
  • NIHcoreStrategic or Co-development PartnerGovernment research funding agency partnership for neurological disease research funding and collaboration.
  • Trieste UniversityminorStrategic or Co-development PartnerInternational academic partnership for neurological biomarker research collaboration.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

NeuroDex competitors and assessment

Company assessment

Emerging players

  • Evelo Biosciences: Although primarily inflammation-focused, Evelo represents the broader class of emerging biomarker-driven biotechs that compete for the same pharma partnership and grant funding pool as NeuroDex.
  • Alamar Biosciences: Ultra-sensitive proteomics platform (NULISA) targeting neurology and inflammation biomarkers. Emerging alternative to NDE-based approaches for CNS biomarker measurement in clinical trials.

Direct peers

  • ADx NeuroSciences: Specialized biomarker assay developer focused on neurodegenerative disease diagnostics (Alzheimer's, Parkinson's). Provides complementary and competing immunoassays for CNS drug development.
  • Quanterix: Simoa ultra-sensitive immunoassay platform widely used for neurology biomarker detection (NfL, p-Tau). Provides competing biomarker measurement technology serving overlapping pharma and academic customers.
  • C2N Diagnostics: Commercial-stage blood-based diagnostics for Alzheimer's disease (PrecivityAD) with CLIA-certified lab. Competes for pharma AD trial stratification contracts and shares NeuroDex's neurology biomarker services model.
  • Amprion: Develops Seed Amplification Assays (SAA/RT-QuIC) for synucleinopathies including Parkinson's and MSA. Directly comparable to NeuroDex's αSyn-SAA diagnostic offering and competes for the same clinical trial biomarker opportunities.

Others

  • Simoa Neurology Biomarker Consortia (academic core labs e.g., Sahlgrenska, ADNI): Academic biomarker core labs running in-house immunoassays for pharma-sponsored studies. They compete indirectly for translational research budgets and provide a benchmark for in-sourcing vs. outsourcing biomarker work.

Broad incumbents

  • Bio-Techne: Large life sciences tools company with extensive neuroscience biomarker reagents, ELISA kits, and proteomics platforms. Competes across NeuroDex's RUO consumables business and serves overlapping pharma/academic customers.
  • Fujirebio: Major clinical diagnostics company with established neurology biomarker menu including CSF assays for AD. Represents a potential IVD partner or competitive incumbent in regulated CNS diagnostics.
  • Roche Diagnostics: Global diagnostics leader with Elecsys neurology biomarker assays (p-Tau181, NfL, GFAP) deployed on widespread clinical instrumentation. Sets pricing and standards in the CNS IVD market NeuroDex aspires to enter.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NeuroDex compliance and trust

Trust signal

Compliance3 records

NeuroDex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroDex leadership team

Management profile

Number of profiles

Profiles2 records

NeuroDex funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroDex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroDex

What does NeuroDex do?

NeuroDex develops and delivers biomarker discovery, translational research, and clinical trial support services built on its proprietary ExoSort Platform for isolating neuron-derived extracellular vesicles (NDEs) from blood samples. The company sells biomarker assay plates, assays, and reagents as research-use-only products and provides end-to-end biomarker solutions for pharmaceutical, biotechnology, and academic clients targeting Parkinson's, Alzheimer's, ALS, and neuroinflammatory diseases.

Is NeuroDex a public or private company?

NeuroDex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NeuroDex founded?

NeuroDex was founded in 2018. It employs 11 to 50 people.

Where is NeuroDex based?

NeuroDex is headquartered in Natick, United States, in the North America region.

How does NeuroDex make money?

Four revenue lines are on record. Biomarker Discovery Services are the primary driver. The others are translational Research Biomarkers, clinical Trial Biomarker Support and neurodiagnostic Platform Products.

Who are NeuroDex's main competitors?

Emerging players on record are Evelo Biosciences and Alamar Biosciences. Direct peers are ADx NeuroSciences, Quanterix, C2N Diagnostics and Amprion. Simoa Neurology Biomarker Consortia (academic core labs e.g., Sahlgrenska, ADNI) is listed as an others. Broad incumbents are Bio-Techne, Fujirebio and Roche Diagnostics.

Does NeuroDex have an API?

No public API is recorded for NeuroDex.

What industry is NeuroDex in?

NeuroDex's product category is Neurological Biomarker Services. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingNeuroDex CEO Presents Blood-Based Biomarker Research at Arthur L. Haas Endowed LectureNeuroDex CEO Erez Eitan will deliver the sixth Arthur L. Haas Endowed Lecture at LSU Health New Orleans on Nov. 11, 2026. His presentation will cover blood-based biomarker research in neurodegenerative diseases, focusing on potential applications in disease monitoring, treatment evaluation, and clinical trials.FinancialContent Business PageNeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALSNeuroDex announced findings from its ExoSORT platform demonstrating that NDE-associated TDP-43 distinguished sporadic ALS patients from healthy controls across multiple independent cohorts, with statistically significant increases ranging from 44% to more than twofold higher. Longitudinal analyses showed TDP-43 levels increased approximately 45% per year in ALS patients and correlated with disease severity, while participants receiving NeuroSense Therapeutics' PrimeC in the Phase 2b PARADIGM trial showed a statistically significant reduction in the biomarker compared to placebo, suggesting potential applications for patient selection and treatment monitoring in neurodegenerative disease.BioSpaceNeuroDex and Stanford Researchers Publish First Evidence of CNS Target Engagement for GLP-1 and PPARγ Agonists Using Blood-Based Neuron-Derived Extracellular VesiclesNeuroDex and Stanford researchers published a study in JCEM showing their ExoSORT platform detects CNS pharmacodynamic effects of pioglitazone and liraglutide from blood. The drugs produced significant, drug-specific changes in Akt–mTOR pathway biomarkers, independent of peripheral insulin and glucose. The findings are exploratory and require prospective, adequately powered studies to confirm.EIN PresswireNeuroDex and Stanford Publish First Blood-Based Evidence of CNS Target Engagement for GLP-1 and PPARγ AgonistsNeuroDex and Stanford researchers published a study in the Journal of Clinical Endocrinology & Metabolism showing that their ExoSORT platform detects central Akt–mTOR signaling changes from blood after metabolic drug treatment. Liraglutide and pioglitazone produced drug-specific changes, with biomarkers correlating to depression symptom improvement. The findings are exploratory, and prospective studies are needed to confirm the signals.BioSpaceNeuroDex Contributes to Landmark Review on Tissue-Specific Extracellular Vesicles and the Future of Liquid BiopsyNeuroDex, Inc., a biotechnology company based in Natick, Massachusetts, announced the publication of a peer-reviewed review article in the Journal of Extracellular Biology on tissue-specific extracellular vesicles and their clinical potential for liquid biopsy diagnostics. The paper identifies the lack of standardized, validated, and reproducible EV enrichment methods as the major challenge facing the field and calls for stronger validation frameworks and methodological rigor. The publication reflects NeuroDex's ongoing mission to advance biomarker platforms and diagnostic tools for neurodegenerative and complex diseases.PR.comNeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS ResearchNeuroDex Inc. has been awarded a Target ALS Biomarker Consortia Grant to develop a biomarker for monitoring amyotrophic lateral sclerosis (ALS) progression. The company will collaborate with Twilight Neuro, BrainEver Pharma, and the National Institute of Neurological Disorders and Stroke to validate this approach using neuron-derived extracellular vesicles.PR NewswireNeuroDex, Inc. and ICV Venture Engineering Fund Announce Closing of Seed Round for NeuroDex, Inc.NeuroDex, Inc., a Massachusetts-based developer of exosome-based diagnostics and neurology tools, completed its seed round of financing in April 2020, led by ICV Venture Engineering Fund I, LLC, following an agreement signed in January 2020. The funding will support the development and expansion of NeuroDex's proprietary ExoSORT™ technology platform, though specific financial terms remain confidential. ICV's investment reflects confidence in NeuroDex's team and vision to develop minimally invasive, blood-based diagnostic tools in the neurology space.